Location History:
- Hants, GB (2013)
- Sutton, GB (2016)
- London, GB (2016 - 2024)
Company Filing History:
11 out of 263 
1 out of 56 
Years Active: 2013-2024
Title: Butrus Atrash: Innovator in Cancer Therapeutics
Introduction
Butrus Atrash, an accomplished inventor based in London, GB, has made significant contributions to the field of cancer treatment through his innovative research. With a notable portfolio consisting of 11 patents, Atrash continues to push the boundaries of scientific discovery aimed at improving therapeutic options for proliferative diseases.
Latest Patents
Among his most recent inventions, Atrash has developed inhibitor compounds that target the spindle checkpoint function of Monospindle 1 (Mps1) kinases. These compounds, defined by specific formulas involving R, Ar, W, X, and Z, exhibit properties that allow them to inhibit Mps1 kinases either directly or indirectly. The implications of these compounds are profound, as they are proposed to serve as therapeutic agents for treating and preventing diseases such as cancer. Additionally, Atrash has outlined processes for the preparation of these compounds and the pharmaceutical compositions that incorporate them.
Career Highlights
Throughout his career, Butrus Atrash has collaborated with notable organizations, including Cancer Research Technology Limited and Cyclacel Limited. His work at these institutions has further anchored his commitment to advancing cancer therapeutics and solidifying his place within the research community.
Collaborations
Atrash has had the privilege of collaborating with esteemed colleagues such as Julian Blagg and Peter William Sheldrake. Together, this diverse team has worked towards innovative solutions in the pharmaceutical industry, focusing on the prevention and treatment of cancer through groundbreaking research.
Conclusion
Through his innovative spirit and commitment to scientific advancement, Butrus Atrash has made remarkable strides in the development of cancer therapeutics. With his 11 patents and a strong collaborative network, he continues to hold a vital role in shaping the future of medicine, particularly in the fight against proliferative diseases.